BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32786276)

  • 1. Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A
    Dai CC; Yang J; Hussein WM; Zhao L; Wang X; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
    ACS Infect Dis; 2020 Sep; 6(9):2502-2512. PubMed ID: 32786276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
    Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
    ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylenimine quantity and molecular weight influence its adjuvanting properties in liposomal peptide vaccines.
    Dai CC; Huang W; Yang J; Hussein WM; Wang J; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
    Bioorg Med Chem Lett; 2021 May; 40():127920. PubMed ID: 33705898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
    Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
    Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
    Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus.
    Yang J; Firdaus F; Azuar A; Khalil ZG; Marasini N; Capon RJ; Hussein WM; Toth I; Skwarczynski M
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
    Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
    Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines.
    Yang J; Boer JC; Khongkow M; Phunpee S; Khalil ZG; Bashiri S; Deceneux C; Goodchild G; Hussein WM; Capon RJ; Ruktanonchai U; Plebanski M; Toth I; Skwarczynski M
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel platform technology for modular mucosal vaccine that protects against streptococcus.
    Zaman M; Ozberk V; Langshaw EL; McPhun V; Powell JL; Phillips ZN; Ho MF; Calcutt A; Batzloff MR; Toth I; Hill GR; Pandey M; Good MF
    Sci Rep; 2016 Dec; 6():39274. PubMed ID: 27976706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
    Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
    Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasally administered polyethylenimine adjuvanted influenza M2 ectodomain induces partial protection against H9N2 influenza A virus infection in chickens.
    Hajam IA; Kim J; Lee JH
    Vet Immunol Immunopathol; 2019 Mar; 209():78-83. PubMed ID: 30885310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS).
    Rivera-Hernandez T; Hartas J; Wu Y; Chuan YP; Lua LH; Good M; Batzloff MR; Middelberg AP
    Vaccine; 2013 Apr; 31(15):1950-5. PubMed ID: 23422147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.